Analysis of EZH2 Genetic Variants on Triple-Negative Breast Cancer Susceptibility and Pathology

Int J Med Sci. 2022 May 29;19(6):1023-1028. doi: 10.7150/ijms.71931. eCollection 2022.

Abstract

Triple-negative breast cancer (TNBC) is the third most common female cancer in Taiwan. EZH2 plays an important role in cancer development through transcriptional repression by chromatin remodeling. However, the expression of EZH2 in breast cancer is highly correlated with tumorigenesis, and patient survival is not matched to TNBC. Furthermore, it has not been determined if specific EZH2 genetic variants are associated with breast cancer risk. In this paper, we evaluated the survival of different types of breast cancer. The results indicated that a lower expression of EZH2 led to poor survival of TNBC patients. Therefore, we aimed at studying the relationship between genetic polymorphisms of EZH2 and susceptibility to TNBC in Taiwan. Four single-nucleotide polymorphisms (SNPs) of EZH2 (rs6950683, rs2302427, rs3757441, and rs41277434) were analyzed by real-time PCR genotyping in 176 patients with TNBC and 1000 cancer-free controls. The results showed that TNBC patients under 60 years old who carried a TC or CC genotype at EZH2 rs6950683 and re3757441 had a tumor size of 20 mm or smaller (T1). Thus, this study is the first to examine the age and mutant genes associated with EZH2 SNPs in TNBC progression and development in Taiwan.

Keywords: EZH2; age; single-nucleotide polymorphism (SNP); triple-negative breast cancer.

MeSH terms

  • Enhancer of Zeste Homolog 2 Protein / genetics
  • Female
  • Genotype
  • Humans
  • Middle Aged
  • Polymorphism, Single Nucleotide
  • Taiwan / epidemiology
  • Triple Negative Breast Neoplasms* / genetics
  • Triple Negative Breast Neoplasms* / pathology

Substances

  • EZH2 protein, human
  • Enhancer of Zeste Homolog 2 Protein